Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

1.54
+0.02051.35%
Volume:26.30K
Turnover:40.34K
Market Cap:17.59M
PE:-0.81
High:1.59
Open:1.59
Low:1.50
Close:1.52
52wk High:7.95
52wk Low:1.42
Shares:11.42M
Float Shares:9.35M
Volume Ratio:0.51
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9054
EPS(LYR):-2.2184
ROE:-335.45%
ROA:-49.76%
PB:6.95
PE(LYR):-0.69

Loading ...

Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025

Reuters
·
Nov 20, 2025

Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition

Reuters
·
Nov 20, 2025

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

TIPRANKS
·
Nov 20, 2025

BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million

Reuters
·
Nov 20, 2025

Vivos Therapeutics Inc - Qtrly Net Loss per Share Basic and Diluted $0.49

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Q3 Gross Profit USD 3.937 Million

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Inc - Revenue $6.8 Mln in Q3 2025

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate

Benzinga
·
Nov 20, 2025

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

GlobeNewswire
·
Nov 19, 2025

Vivos Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 17, 2025

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Nov 17, 2025

Vivos Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $7

THOMSON REUTERS
·
Nov 17, 2025

Vivos Therapeutics Delays Q3 Report Amid Acquisition

TIPRANKS
·
Nov 15, 2025

BRIEF-Vivos Therapeutics Files For Non-Timely 10-Q With US SEC

Reuters
·
Nov 15, 2025

Vivos Therapeutics Inc -Anticipates That Its Revenue Increased by Over 50% for Three Months Ended September 30

THOMSON REUTERS
·
Nov 15, 2025

Vivos Therapeutics Inc: Files for Non-Timely 10-Q With U.S. SEC

THOMSON REUTERS
·
Nov 15, 2025

Vivos Therapeutics Delays Quarterly Financial Report Filing

Reuters
·
Nov 15, 2025

Vivos Therapeutics Inc. held annual shareholder meeting

Reuters
·
Nov 05, 2025

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

GlobeNewswire
·
Sep 30, 2025